Form 4: Dyne Therapeutics CEO Sells Shares for Tax Obligations

Dyne Therapeutics CEO John Cox sold 2,662 shares of common stock at a weighted average price of $20.72 to cover tax withholding obligations related to RSU vesting.

Summary

• CEO John Cox sold 2,662 shares of Dyne Therapeutics common stock on December 5, 2025.
• The sale was executed at a weighted average price of $20.72 per share, with prices ranging from $20.58 to $20.96.
• This transaction was non-discretionary, occurring automatically to satisfy tax withholding obligations from restricted stock unit (RSU) vesting, and was made pursuant to a Rule 10b5-1 plan.
• Following the transaction, Mr. Cox directly beneficially owns 196,877 shares, which includes 108,976 unvested RSUs.
• Additionally, he indirectly beneficially owns 72,000 shares held across four trusts for the benefit of a child.
• Mr. Cox paid $31,111.88 to Dyne Therapeutics for a short-swing profit realized from the sale of 2,662 shares, which was matchable with a purchase of 100,000 shares on July 14, 2025, under Section 16(b) of the Exchange Act.

Sentiment

Score: 5

Explanation: Neutral. The transaction is a non-discretionary sale for tax purposes, which is a common occurrence for executives. The short-swing profit repayment is a minor negative but resolved.

Positives

• The sale was non-discretionary and pre-planned under a Rule 10b5-1 plan, indicating a structured approach to equity management rather than a discretionary decision to sell.
• The CEO continues to hold a significant number of shares directly and indirectly, including a substantial amount of unvested RSUs, aligning his interests with shareholders.

Negatives

• The CEO realized a short-swing profit of $31,111.88, which had to be paid back to the company, indicating a potential oversight in transaction timing or compliance with Section 16(b) rules.

Risks

• Potential for negative market perception if the sale is misinterpreted as a lack of confidence, despite being for tax purposes.
• Compliance risk related to Section 16(b) short-swing profit rules, as evidenced by the required payment to the issuer.

Future Outlook

The filing does not contain specific forward-looking statements or guidance regarding the company's future performance or strategic direction. It primarily reports an insider transaction.

Management Comments

• The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4.

Industry Context

This Form 4 filing is a routine disclosure of an insider transaction, common across all publicly traded companies. It does not provide specific insights into Dyne Therapeutics' competitive position or broader industry trends in biotechnology, but rather reflects an individual executive's equity management.

Comparison to Industry Standards

• NA

Related Party Transactions

• The indirect beneficial ownership through trusts for the benefit of a child of the Reporting Person could be considered a related party arrangement for disclosure purposes, though it is a common structure for executive estate planning.

Stakeholder Impact

• Shareholders: Minor dilution from the sale, but the non-discretionary nature and continued significant holdings by the CEO suggest no immediate negative signal. The Section 16(b) repayment benefits the company.
• Employees/Customers/Suppliers/Creditors: No direct impact from this insider transaction.

Next Steps

• The Reporting Person undertakes to provide full information regarding the number of shares sold at each separate price within the reported range upon request.

Key Dates

Recommendation

This Form 4 filing details a routine, non-discretionary sale of shares by Dyne Therapeutics' CEO, John Cox, to cover tax obligations related to RSU vesting. While a short-swing profit was realized and repaid, this is a compliance matter rather than an indicator of fundamental business performance or management's long-term outlook. The CEO retains substantial direct and indirect ownership, aligning his interests with shareholders. The transaction itself does not provide new information to warrant a change in investment thesis, thus a 'hold' recommendation is appropriate.

Keywords

Dyne Therapeutics, DYN, Form 4, Insider Trading, Stock Sale, CEO, John Cox, RSU Vesting, Tax Withholding, 10b5-1 Plan, Section 16(b)